Attruby Strengthens Position as ATTR-CM Treatment Following Wainua Trial Failure

Recent cardiology clinical trials have reinforced BridgeBio's Attruby as a preferred treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). This follows AstraZeneca's Phase III Wainua trial failing to meet its primary endpoint for the same condition. The outcome significantly impacts treatment strategies for ATTR-CM patients.